Washington, DC: NORML staffers on Monday hand-delivered over 10,000 written comments from US citizens calling on federal and international agencies to amend the international prohibition of cannabis. The public comments, which were requested earlier this month by the US Food and Drug Administration, will be considered as part of the World Health Organization’s ongoing review of the plant’s international classification.
Under international treaties, the marijuana plant is classified in the most restrictive schedules available for controlled substances. NORML maintains that this scheduling does not accurately reflect the plant’s widespread therapeutic acceptance and relatively low abuse potential.
“The United Nation’s international prohibition of cannabis is a relic from a bygone era,” NORML Deputy Director Paul Armentano said. “This decision, which was largely a political one made over 50 years ago, does not accurately reflect either the available science or the rapidly changing political and cultural status of cannabis worldwide.”
Members of NORML’s Board of Directors also submitted their own written testimony to the FDA, opining: “In general, the safety, dependence, and usage profile of cannabis compares favorably to alcohol, tobacco, and other unscheduled substances. For this reason, NORML believes that cannabis [ultimately] should be withdrawn from the treaty framework entirely.”
For more information, contact Justin Strekal, NORML Political Director, at (202) 483-5500.